Radon and Ovarian Cancer; FDA Rejects Drug Again; Missed Chances for Genomic Testing

High levels of residential radon were linked to a roughly 30% higher risk for ovarian cancer in postmenopausal women, an analysis of the Women’s Health Initiative showed. (JAMA Network Open)

Meanwhile, occupational exposure to asbestos-free talc was not associated with an increased risk of lung cancer, mesothelioma, or laryngeal cancer in a meta-analysis. (Journal of Thoracic Oncology)

The FDA for a second time declined to approve vusolimogene oderparepvec (RP1), Replimune’s virus-derived immunotherapy for advanced melanoma, citing insufficient evidence of benefit.

And Orca Bio said the agency delayed a decision to approve or reject its allogeneic T-cell immunotherapy for hematologic malignancies.

The FDA cleared the Onclarity at-home human papillomavirus (HPV) self-collection ‌kit for use with an approved test for cervical cancer screening, Waters Corporation announced.

A Connecticut woman who alleged her cervical cancer went undetected for years after her doctor failed to follow protocols for monitoring high-risk HPV strains was awarded $49 million by a jury. (WTNH)

Adults who remain single have a significantly higher risk of developing cancer versus those who marry, according to a large U.S. study. (Cancer Research Communications)

A low-cost assay that sequences cell-free DNA from one blood sample showed promise in detecting liver, lung, ovarian, and stomach cancers. (UCLA Health)

A study of real-world lung cancer reports found that artificial intelligence-generated summaries were more complete, while maintaining correctness with low potential harm, compared with physician summaries. (JCO: Clinical Cancer Informatics)

Most patients with advanced or metastatic cancers — particularly Black or Hispanic patients and those with low socioeconomic status — never receive tumor genomic testing, a retrospective cohort study suggested. (JAMA Network Open)

Amplia Therapeutics said recruitment was halted for a trial evaluating investigational narmafotinib for advanced pancreatic cancer due to dose-limiting toxicity events with modified FOLFIRINOX chemotherapy.

FDA lifted a partial clinical hold on a phase II study evaluating lorigerlimab — a bispecific that simultaneously targets PD-1 and CTLA-4 — in patients with gynecologic cancers, MacroGenics said.

Former Sen. Ben Sasse (R-Neb.) talked about facing death as he battles metastatic pancreatic cancer. (New York Times)

Cambodia’s king said he will undergo treatment for prostate cancer. (AP)

Please enable JavaScript to view the comments powered by Disqus.